Pharmaceutical Products: 65%
Medical Devices: 20%
Biotechnology: 15%

China: 50%
USA: 30%
Europe: 20%

Sichuan Kelun Pharmaceutical Co., Ltd. generates the majority of its revenue from the sale of pharmaceutical products, accounting for 65% of total revenue. This includes both prescription and over-the-counter medications. The medical devices segment contributes 20% to revenue, while the biotechnology segment accounts for 15%.

Geographically, China is the company's largest market, representing 50% of revenue. The USA follows with a 30% share, attributed to strategic partnerships and expanding distribution networks. Europe contributes 20% to revenue, with growing demand for innovative medications and biotechnological solutions.

Main production sites:

• Chengdu, Sichuan, China
• Luzhou, Sichuan, China
• Additional sites in various provinces of China

Sichuan Kelun Pharmaceutical Co., Ltd. is a leading pharmaceutical company in China that mainly produces its products in various manufacturing facilities within the country. The main production facilities are located in Chengdu and Luzhou, both in the province of Sichuan. In addition, the company operates additional production plants in various provinces to meet demand both in the domestic and international markets. This strategic distribution of production sites enables the company to operate efficiently and leverage logistical advantages.

Focus on International Expansion: Sichuan Kelun Pharmaceutical Co., Ltd. plans to expand its presence in international markets, especially in emerging countries.

Investments in Research and Development: The company has increased its investments in R&D to develop innovative drugs and expand its product pipeline.

Strategic Partnerships: Sichuan Kelun aims to collaborate with other pharmaceutical companies to leverage synergies and accelerate market access.

The company is pursuing a growth strategy based on a combination of geographic expansion, enhanced research and development, and strategic alliances. These measures are intended to increase competitiveness and tap into new revenue sources.

Main raw materials: Active pharmaceutical ingredients (APIs), excipients, packaging materials
Import countries: India, China, Germany

Sichuan Kelun Pharmaceutical Co., Ltd. mainly imports active pharmaceutical ingredients (APIs) that are essential for the production of their pharmaceutical products. India is one of the largest suppliers of APIs worldwide and therefore a significant trading partner for the company.

In addition, Sichuan Kelun also sources excipients and packaging materials necessary for the production and distribution of their products. Germany is known for manufacturing high-quality pharmaceutical excipients and packaging solutions, making it another source of imports.

This import strategy enables the company to manufacture high-quality products and remain competitive in the international market.

Market share in China: 5% (2024, estimated)
Research & Development (R&D) expenses: 1.2 billion CNY (2024)
International business growth: 10% (2024)

Sichuan Kelun Pharmaceutical Co., Ltd. has established itself as one of the leading manufacturers of pharmaceutical products in China. A key competitive advantage of the company lies in its strong presence in the domestic market, where it holds an estimated market share of about 5%. This enables the company to benefit from the growing demand for pharmaceutical products in China.

Another advantage is the commitment to research and development. With expenses of 1.2 billion CNY in 2024, the company demonstrates its willingness to invest in innovative products and technologies, thereby strengthening its competitiveness in the long term.

Furthermore, Sichuan Kelun is experiencing a growth of 10% in its international business, indicating successful expansion strategies and the exploration of new markets. This diversification of revenue sources helps to reduce risk and solidify the global competitive advantage.

Institutional Investor Share: 28% (estimated, 2025)
Insider Buys/Sells: No significant transactions in the last year (2025)

The institutional investor share in Sichuan Kelun Pharmaceutical Co., Ltd. is estimated to be around 28%. This figure reflects the confidence of institutional investors in the long-term development of the company.

In 2025, there were no significant insider buys or sells, indicating a stable assessment of the company's value by management. This may suggest that the management does not expect any short-term changes in the company's value.

Market Share Sichuan Kelun Pharmaceutical: 5.2% (2025, estimated)

Top Competitors and Their Market Shares:

1. Sinopharm Group Co., Ltd.: 12.5%
2. Shanghai Pharmaceuticals Holding Co., Ltd.: 9.8%
3. China Resources Pharmaceutical Group Limited: 8.7%
4. CSPC Pharmaceutical Group Limited: 7.4%
5. Sichuan Kelun Pharmaceutical Co., Ltd.: 5.2%
6. Hengrui Medicine: 4.9%
7. Tasly Pharmaceutical Group Co., Ltd.: 4.3%
8. Harbin Pharmaceutical Group Co., Ltd.: 3.9%
9. Yunnan Baiyao Group Co., Ltd.: 3.5%
10. Jiangsu Hengrui Medicine Co., Ltd.: 3.2%

Moat of Sichuan Kelun Pharmaceutical:

Sichuan Kelun Pharmaceutical has a moderate moat, mainly supported by its strong presence in the intravenous infusion solutions sector and its innovation in biopharmaceutical research. The company consistently invests in research and development to introduce new products to the market and enhance existing ones.

In comparison to its competitors, Sinopharm has a significant advantage due to its comprehensive distribution infrastructure and wide range of products, enabling a larger market share. Shanghai Pharmaceuticals and China Resources Pharmaceutical also benefit from strong distribution networks and diversified product lines.

While Sichuan Kelun is well positioned in certain niche markets, some of the larger competitors have a stronger moat due to their size, network, and financial resources. To remain competitive, Sichuan Kelun must continue to invest in innovation and strategic partnerships.

Revenue growth: 8.5% (2024) Research and development expenses: 12% of revenue (2024) Market share in the generic sector in China: 10% (2024)

Sichuan Kelun Pharmaceutical Co., Ltd. recorded a revenue growth of 8.5% in 2024, indicating strong demand for its products and effective market penetration. The company is also investing significantly in research and development, with 12% of revenue allocated to this area. This suggests a strategic focus to remain competitive through innovation and new product development.

With a 10% market share in the generic sector in China, Sichuan Kelun is shown to hold a significant position in one of the world's largest pharmaceutical markets. These factors indicate that the company is well positioned to benefit from future growth opportunities.

Overall, Sichuan Kelun Pharmaceutical could be an attractive investment, especially for investors focusing on long-term growth and innovation in the pharmaceutical sector.

Dividend Yield: 2.5% (2024) Dividend History: Consistent payout over the last 5 years

Sichuan Kelun Pharmaceutical Co., Ltd. has distributed dividends in recent years, with a dividend yield of approximately 2.5% in 2024. The company has a reliable dividend history with continuous payouts over the past five years.

The reliability of dividend payment is supported by the stable business model and solid financial performance of the company. Analysts expect that Sichuan Kelun will also be able to pay dividends in the coming years, provided that no significant negative market changes occur.